{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T05:01:21Z","timestamp":1755925281875},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"Supplement_6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"DOI":"10.1086\/429337","type":"journal-article","created":{"date-parts":[[2005,4,15]],"date-time":"2005-04-15T19:04:52Z","timestamp":1113591892000},"page":"S409-S413","source":"Crossref","is-referenced-by-count":38,"title":["Successful Use of Amphotericin B Lipid Complex in the Treatment of Cryptococcosis"],"prefix":"10.1093","volume":"40","author":[{"given":"Larry M.","family":"Baddour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Perfect","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Ostrosky-Zeichner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,5,1]]},"reference":[{"key":"key\n\t\t\t\t20171014025606_ref1","first-page":"765","article-title":"Fungal infections other than candidiasis","volume-title":"Therapy of infectious diseases","author":"McKinsey","year":"2003"},{"key":"key\n\t\t\t\t20171014025606_ref2","first-page":"391","article-title":"New trends in the epidemiology of cryptococcosis in France: analysis of 2120 cases from the national epidemiological registry (1985\u20132001) [abstract 883]","volume-title":"Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego)","author":"Dromer","year":"2002"},{"key":"key\n\t\t\t\t20171014025606_ref3","article-title":"Trends in incidence of clinical manifestations of HIV infection and antiretroviral prescriptions in French university hospitals [abstract 182]","volume-title":"Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago)","author":"Castagliola","year":"1998"},{"key":"key\n\t\t\t\t20171014025606_ref4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199201093260202","article-title":"Comparisons of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis","volume":"326","author":"Saag","year":"1992","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014025606_ref5","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1128\/AAC.33.10.1735","article-title":"Treatment of experimental cryptococcus meningitis and disseminated candidiasis with SCH 39304","volume":"33","author":"Perfect","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014025606_ref6","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJM200106283442604","article-title":"Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection","volume":"344","author":"Winston","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014025606_ref7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/33.1.73","article-title":"Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidiasis","volume":"33","author":"Perfect","year":"1994","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 6","key":"key\n\t\t\t\t20171014025606_ref8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/429329","article-title":"Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry: introduction","volume":"40","author":"Pappas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014025606_ref9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/infdis\/157.4.624","article-title":"Cryptococcal meningitis in patients with AIDS","volume":"157","author":"Dismukes","year":"1988","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014025606_ref10","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJM198909213211205","article-title":"Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome","volume":"321","author":"Chuck","year":"1989","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014025606_ref11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-104-2-234","article-title":"Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment","volume":"104","author":"Zuger","year":"1986","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171014025606_ref12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u201cgold standard\u201d","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014025606_ref13","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/319211","article-title":"Mortality and costs of acute renal failure associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014025606_ref14","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","article-title":"Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis","volume":"29","author":"Wingard","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014025606_ref15","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.2000.18.12.2476","article-title":"Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"18","author":"Cagnoni","year":"2000","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171014025606_ref16","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"Suppl B","key":"key\n\t\t\t\t20171014025606_ref17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/28.suppl_B.93","article-title":"Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients","volume":"28","author":"Chopra","year":"1991","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl B","key":"key\n\t\t\t\t20171014025606_ref18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/28.suppl_B.73","article-title":"Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients","volume":"28","author":"Ringden","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014025606_ref19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/30.4.535","article-title":"Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared to conventional amphotericin B in neutropenic patients","volume":"30","author":"Moreau","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014025606_ref20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.42.4.899","article-title":"Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis","volume":"42","author":"Clemons","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014025606_ref21","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (Ambisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014025606_ref22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinids\/22.2.315","article-title":"Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS","volume":"22","author":"Sharkey","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014025606_ref23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/40\/Supplement_6\/S409\/20906603\/40-Supplement_6-S409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T16:59:42Z","timestamp":1550077182000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/40\/Supplement_6\/S409\/273210\/Successful-Use-of-Amphotericin-B-Lipid-Complex-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":23,"journal-issue":{"issue":"Supplement_6","published-online":{"date-parts":[[2005,5,1]]},"published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1086\/429337","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,5,1]]},"published":{"date-parts":[[2005,5,1]]}}}